{
    "clinical_study": {
        "@rank": "75469", 
        "arm_group": {
            "arm_group_label": "gemcitabine plus cisplatin", 
            "arm_group_type": "Experimental", 
            "description": "gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on  days 1,8,15 as a 30 minute infusion  and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of neoadjuvant gemcitabine and cisplatin (gem/cis) in\n      locally advanced bladder cancer."
        }, 
        "brief_title": "Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Patients with locally advanced transitional cell bladder cancer receive 3 cycles of\n      neoadjuvant gemcitabine/cisplatin before radical cystectomy.\n\n      Patients with histologically confirmed clinical stage T2-T4a, N0-2 bladder cancer  are going\n      to be included.  After  CT scan of the thorax and abdomen plus MRI of the pelvis patient\n      receive chemotherapy.\n\n      Pathologic response rate will be assessed after surgery by the institutional pathologic\n      review. Safety is going to be assessed according to the National Cancer Institute Common\n      Toxicity Criteria (CTC,version 3.0)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age\n\n          -  histologically confirmed stage T2, T3 or T4a urothelial bladder cancer with   N0-N2\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\n          -  bone marrow reserve (neutrophil count >1500 cells per \u03bcL,platelet count >100 000 per\n             \u03bcL) count\n\n          -  hepatic function (serum bilirubin <2,5 times the upper limit of normal, serum\n             aminotransferase \u22642,5 times the upper limit of normal).\n\n          -  renal function with a creatinine clearance >60ml/min\n\n        Exclusion Criteria:\n\n          -  metastatic disease\n\n          -  serious or uncontrolled concurrent medical illness\n\n          -  pregnancy\n\n          -  history of other malignancies (with the exception of excised cervical or basal skin\n             or squamous-cell carcinoma)\n\n          -  non-transitional cell bladder cancer\n\n          -  creatinine clearance <60ml/min"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801644", 
            "org_study_id": "Bladder Cancer-001", 
            "secondary_id": "Bladder Cancer-001"
        }, 
        "intervention": {
            "arm_group_label": "gemcitabine plus cisplatin", 
            "description": "gemcitabine 1000 mg/m2 on  days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion", 
            "intervention_name": "gemcitabine plus cisplatin", 
            "intervention_type": "Drug", 
            "other_name": "gemzar (gemcitabine) plus cisplatin (= cisplatin)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bladder cancer", 
            "neoadjuvant chemotherapy", 
            "gem/cis"
        ], 
        "lastchanged_date": "February 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1020"
                }, 
                "name": "Barmherzige Br\u00fcder Vienna"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer", 
        "other_outcome": {
            "description": "pfs will be assessed avery 3 months in the first year after radical cystectomy, every 6 months in the second year, and yearly from the 3rd year up to a minimum follow up of 5 years", 
            "measure": "progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "up to 5 years after including the last patient"
        }, 
        "overall_official": {
            "affiliation": "Barmherzige Br\u00fcder Vienna", 
            "last_name": "Johannes Meran, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "evaluation of the pathologic response rate after 3 cycles of neoadjuvant gemcitabine/cisplatin at time of radical cystectomy", 
            "measure": "pathologic response rate", 
            "safety_issue": "No", 
            "time_frame": "at time of surgery"
        }, 
        "reference": {
            "PMID": "18823036", 
            "citation": "Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7. doi: 10.1002/cncr.23848."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801644"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Barmherzige Br\u00fcder Vienna", 
            "investigator_full_name": "Johannes Meran", 
            "investigator_title": "Prof. Dr.Johannes Meran", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "to assess the safety of neoadjuvant gemcitabine/cisplatin in bladder cancer", 
            "measure": "safety,  number of participants with adverse events and grade of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "adverse events will be evaluated after every 6 months"
        }, 
        "source": "Barmherzige Br\u00fcder Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Barmherzige Br\u00fcder Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2007", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}